Hypotension with intravenous immunoglobulin therapy: Importance of pH and dimer formation

Biologicals

Volumn 31, Issue 4, 2003, Pages 277-286

  Kroez, Monika ^a   Kanzy, Ernst Jürgen ^a   Gronski, Peter ^a   Dickneite, Gerhard ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Experimental autoimmune encephalomyelitis; Fc; Hypotension; Immunoglobulin G dimer; Intravenous immunoglobulin

Indexed keywords

BERIGLOBIN; FC RECEPTOR; GAMMA VENIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; PROTEIN G SEPHAROSE;

ACIDITY; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIMERIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STORAGE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; HYPOTENSION; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; INDUCED HYPOTENSION; MACROPHAGE; MALE; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0242574977     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2003.09.001     Document Type: Article

References (29)

1. Choudhry V.P., Mahapatra M., Kashyap R. Immunoglobulin therapy in immunohematological disorders. Indian J Pediatr. 65:1998;681-690.
2. Mouthon L., Guillevin L. Intravenous immunoglobulins: anti-infection indications. Ann Med Interne (Paris). 151:2000;136-143.
3. Helmke K. Current applications of immunoglobulin therapy. Fortschr Med Orig. 112:1994;213-217.
4. Achiron A., Miron S. Intravenous immunoglobulins (IVIG) in the treatment of multiple sclerosis. Ann Med Interne (Paris). 151:(Suppl 1):2000;S41-S44.
5. Bridonneau P., Marcilly H., Vernois-Martin M., Goigoux P., Bourdel V., Laulan A., et al. Liquid pasteurization of an immunoglobulin preparation without stabilizer: effects on its biological and biochemical properties. Vox Sang. 70:1996;203-209.
6. Duhem C., Dicato M.A., Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 97:(Suppl 1):1994;79-83.
7. Sherer Y., Levy Y., Langevitz P., Rauova L., Fabrizzi F., Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 62:2001;133-137.
8. Bleeker W.K., Agterberg J., Rigter G., de Vries-van Rossen A., Bakker J.C. An animal model for the detection of hypotensive side effects of immunoglobulin preparations. Vox Sang. 52:1987;281-290.
9. Bleeker W.K., Teeling J.L., Verhoeven A.J., Rigter G.M.M., Agterberg J., Koenderman A.H., et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood. 95:2000;1856-1861.
10. Achiron A., Gabbay U., Gilad R., Hassin-Baer S., Barak Y., Gornish M., et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology. 50:1998;398-402.
11. Bleeker W.K., Agterberg J., Rigter G., Van Rooijen N., Bakker J.C. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin Exp Immunol. 77:1989;338-344.
12. Handley D.A., Van Valen R.G., Melden M.K., Flury S., Lee M.L., Saunders R.N. Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist. Immunopharmacol. 12:1986;11-16.
13. Makula M.F., Coquet B., Plan R., Imbert C., Peyron L., Moulin J.C., et al. Intravenous immunoglobulins: can the blood pressure response in laboratory animals be considered a predictive criterion for good clinical tolerance? Dev Biol Stand. 67:1987;257-265.
14. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia: a review. Am J Med. 76:(Suppl 3a):1984;53-60.
15. Jenei B., Lazar G., Bartha K., Mihalik R., Medgyesi G.A. Hypotensive action of aggregated IgG in rats. Study of the unresponsiveness to a second dose following restoration of the blood pressure. Agents Actions. 42:1994;63-66.
16. Jenei B., Lazar G., Bartha K., Medgyesi G.A. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). Agents Actions. 32:1991;333-338.
17. Good R.A., Lorenz E. Historic aspects of intravenous immunoglobulin therapy. Cancer. 68:(Suppl 6):1991;1415-1421.
18. Gronski P., Bauer R., Bodenbender L., Kanzy E.J., Schmidt K.H., Zilg H., et al. On the nature of IgG dimers. I. Dimers in human polyclonal IgG preparations: kinetic studies. Behring Inst Mitt. 82:1988;127-143.
19. Tankersley D.L., Preston M.S., Finlayson J.S. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol. 25:1988;41-48.
20. Schwartz R.S. Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25. Am J Med. 83:(Suppl 4a):1987;46-51.
21. Nisini R., Le Moli S., Matricardi P.M., Fattorossi A., D'Amelio R. A comparative in vitro study of low pH and enzyme treated immunoglobulin preparation for intravenous use. J Clin Lab Immunol. 29:1989;193-197.
22. Tanaka K., Sawatani E., Dias G.A., Shigueoka E.M., Campos T.C., Nakao H.C., et al. High quality human immunoglobulin G purified from Cohn fractions by liquid chromatography. Braz J Med Biol Res. 33:2000;27-30.
23. Mollnes T.E., Andreassen I.H., Høgåsen K., Hack C.E., Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol. 34:1997;719-729.
24. Mancilla-Ramirez J., Nurko-Shein S., Castellanos-Cruz C., Santos-Preciado J.I. Therapeutic effectiveness of an intravenous immunoglobulin with pH 4.25 in experimental neonatal sepsis caused by Klebsiella pneumoniae. Bol Med Hosp Infant Mex. 46:1989;89-93.
25. Emerson T.E. Jr, Collins M.S., Budinger M.D. Use of a new, low-pH immunoglobulin G preparation during episodes of bacteremia in the rat. Rev Infect Dis. 8:(Suppl 4):1986;S409-S419.
26. Pirofsky B. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25. Rev Infect Dis. 8:(Suppl 4):1986;S457-S463.
27. Joyner M., Lee R., Hegde U.M. A new IVIgG preparation (IVIgG pH 4.25): preliminary results for the treatment of immune thrombocytopenia. J Infect. 15:(Suppl 1):1987;51-54.
28. Skull S., Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child. 74:1996;527-530.
29. Louie R.E., Galloway C.J., Dumas M.L., Wong M.F., Mitra G. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals. 22:1994;13-19.